2020Diabetes & obesityHeart failure4304 patients

DAPA-CKD

Therapy group: SGLT2 inhibitors · Therapy: Dapagliflozin in chronic kidney disease

Dapagliflozin reduced kidney failure progression, end-stage kidney disease and renal or cardiovascular death in chronic kidney disease patients, with or without diabetes.

Published in N Engl J Med (2020)

Question: Does dapagliflozin reduce kidney and cardiovascular events in patients with chronic kidney disease, with or without type 2 diabetes?
Design: Phase 3, 1:1 randomized, quadruple-masked, placebo-controlled trial of 4304 participants. Median follow-up was 2.4 years, and the independent data monitoring committee recommended stopping the trial early for efficacy.
Population: Adults with chronic kidney disease, with an estimated GFR of 25 to 75 ml per minute per 1.73 m2 and a urinary albumin-to-creatinine ratio of 200 to 5000, with or without type 2 diabetes.
Intervention: Dapagliflozin 10 mg once daily.
Control: Placebo matching dapagliflozin.
Primary outcome: Composite of a sustained decline in estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.
Results: The primary outcome occurred in 197 of 2152 participants (9.2%) with dapagliflozin and 312 of 2152 (14.5%) with placebo (HR 0.61; 95% CI 0.51 to 0.72; P<0.001; number needed to treat 19). All-cause death occurred in 4.7% with dapagliflozin vs 6.8% with placebo (HR 0.69; 95% CI 0.53 to 0.88; P = 0.004).
Safety: The known safety profile of dapagliflozin was confirmed.
Conclusion: In patients with chronic kidney disease, with or without diabetes, dapagliflozin significantly reduced the risk of the composite kidney and cardiovascular outcome versus placebo, with similar effects in patients with and without type 2 diabetes.
Why it matters: It extended the benefit of SGLT2 inhibitors to patients with chronic kidney disease regardless of diabetes status, establishing them as part of the treatment of this population.

Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.

Generated on October 14, 2026

Sources

Original publication on PubMed (PMID 32970396) ↗Dapagliflozin in Patients with Chronic Kidney Disease.
Journal article (DOI) ↗
ClinicalTrials.gov record (NCT03036150) ↗

Videos explaining it

DAPA-CKD Trial - Clara Inés Saldarriaga, MD.

SCC · Sociedad Colombiana de Cardiología y Cirugía Cardiovascular ↗9:24Video page

Source: Sociedad Colombiana de Cardiología y Cirugía Cardiovascular · YouTube
Date: 9 Sept 2020
Audio: Spanish
Subtitles: MultilingualYouTube
Audio transl.: None

All videos explaining it · 6 videos